TY - JOUR
T1 - Chronic Neutrophilic Leukemia
T2 - Current and Future Perspectives
AU - Venugopal, Sangeetha
AU - Mascarenhas, John
N1 - Publisher Copyright:
© 2018 Elsevier Inc.
PY - 2019/3
Y1 - 2019/3
N2 - Chronic neutrophilic leukemia (CNL) is a BCR-ABL1–negative myeloproliferative neoplasm with notably dismal survival. The current 2016 World Health Organization classification of myeloid neoplasms enables clinicians to unequivocally differentiate CNL from its comparable myelodysplastic/myeloproliferative neoplasm overlap syndromes. Additionally, the gradual emergence of next-generation sequencing has progressively expanded our evolving understanding of the molecular pathogenesis of CNL and its therapeutic potential. Hematopoietic stem-cell transplantation remains the primary therapeutic option for the effective treatment of CNL. In this comprehensive review, we highlight the contemporaneous classification, diagnostic criteria, and molecular pathogenesis of CNL. We also discuss the therapeutic implications of the heterogeneous molecular fingerprint of CNL, focusing on emerging targeted therapies, specifically inhibitors of JAK and MAPK signaling pathways.
AB - Chronic neutrophilic leukemia (CNL) is a BCR-ABL1–negative myeloproliferative neoplasm with notably dismal survival. The current 2016 World Health Organization classification of myeloid neoplasms enables clinicians to unequivocally differentiate CNL from its comparable myelodysplastic/myeloproliferative neoplasm overlap syndromes. Additionally, the gradual emergence of next-generation sequencing has progressively expanded our evolving understanding of the molecular pathogenesis of CNL and its therapeutic potential. Hematopoietic stem-cell transplantation remains the primary therapeutic option for the effective treatment of CNL. In this comprehensive review, we highlight the contemporaneous classification, diagnostic criteria, and molecular pathogenesis of CNL. We also discuss the therapeutic implications of the heterogeneous molecular fingerprint of CNL, focusing on emerging targeted therapies, specifically inhibitors of JAK and MAPK signaling pathways.
KW - CSF3R
KW - JAK-STAT
KW - Myeloproliferative neoplasm
KW - Ruxolitinib
KW - SETBP1
UR - http://www.scopus.com/inward/record.url?scp=85058710799&partnerID=8YFLogxK
U2 - 10.1016/j.clml.2018.11.012
DO - 10.1016/j.clml.2018.11.012
M3 - Review article
C2 - 30581159
AN - SCOPUS:85058710799
SN - 2152-2650
VL - 19
SP - 129
EP - 134
JO - Clinical Lymphoma, Myeloma and Leukemia
JF - Clinical Lymphoma, Myeloma and Leukemia
IS - 3
ER -